

# Peter J Newman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1846568/publications.pdf>

Version: 2024-02-01

27  
papers

2,858  
citations

471509

17  
h-index

610901

24  
g-index

27  
all docs

27  
docs citations

27  
times ranked

3355  
citing authors

#	ARTICLE	IF	CITATIONS
1	PECAM-1 (CD31) Cloning and Relation to Adhesion Molecules of the Immunoglobulin Gene Superfamily. <i>Science</i> , 1990, 247, 1219-1222.	12.6	918
2	Signal Transduction Pathways Mediated by PECAM-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 953-964.	2.4	364
3	Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). <i>Current Opinion in Hematology</i> , 2016, 23, 253-259.	2.5	347
4	The Neutrophil-specific Antigen CD177 Is a Counter-receptor for Platelet Endothelial Cell Adhesion Molecule-1 (CD31). <i>Journal of Biological Chemistry</i> , 2007, 282, 23603-23612.	3.4	205
5	Individually Distinct Ig Homology Domains in PECAM-1 Regulate Homophilic Binding and Modulate Receptor Affinity. <i>Journal of Biological Chemistry</i> , 1996, 271, 11090-11098.	3.4	168
6	Inhibition of antigen-receptor signaling by Platelet Endothelial Cell Adhesion Molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56lck. <i>Blood</i> , 2001, 97, 2351-2357.	1.4	130
7	Antibodies Against the First Ig-Like Domain of Human Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) That Inhibit PECAM-1-Dependent Homophilic Adhesion Block In Vivo Neutrophil Recruitment. <i>Journal of Immunology</i> , 2000, 164, 452-462.	0.8	107
8	PECAM-1 (CD31) Expression Modulates Bleeding Time in Vivo. <i>American Journal of Pathology</i> , 2000, 157, 75-81.	3.8	103
9	Endothelial cell PECAM-1 confers protection against endotoxic shock. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H159-H164.	3.2	95
10	Relative contribution of PECAM-1 adhesion and signaling to the maintenance of vascular integrity. <i>Journal of Cell Science</i> , 2011, 124, 1477-1485.	2.0	87
11	Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents. <i>Blood</i> , 2006, 108, 908-914.	1.4	62
12	Structural basis for PECAM-1 homophilic binding. <i>Blood</i> , 2016, 127, 1052-1061.	1.4	49
13	Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia. <i>Blood</i> , 2013, 122, 321-327.	1.4	47
14	CRISPR/Cas9-mediated conversion of human platelet alloantigen allotypes. <i>Blood</i> , 2016, 127, 675-680.	1.4	45
15	Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab) <sub>2</sub> in an in vivo mouse model of alloimmune thrombocytopenia. <i>Transfusion</i> , 2009, 49, 265-270.	1.6	28
16	Regulation of Endothelial Cell Barrier Function by Antibody-driven Affinity Modulation of Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1). <i>Journal of Biological Chemistry</i> , 2014, 289, 20836-20844.	3.4	25
17	Platelet Activation and Thrombus Formation over IgG Immune Complexes Requires Integrin $\alpha$ IIb $\beta$ 3 and Lyn Kinase. <i>PLoS ONE</i> , 2015, 10, e0135738.	2.5	25
18	High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PIA1). <i>Blood Advances</i> , 2018, 2, 3001-3011.	5.2	18

#	ARTICLE	IF	CITATIONS
19	Restoration of Responsiveness of Phospholipase C $\beta$ 2-Deficient Platelets by Enforced Expression of Phospholipase C $\beta$ 1. PLoS ONE, 2015, 10, e0119739.	2.5	9
20	Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia. Blood Advances, 2021, 5, 3552-3562.	5.2	7
21	Atomic Level Dissection of the Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1) Homophilic Binding Interface: Implications for Endothelial Cell Barrier Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 193-204.	2.4	6
22	Overlapping and unique substrate specificities of ST3GAL1 and 2 during hematopoietic and megakaryocytic differentiation. Blood Advances, 2022, 6, 3945-3955.	5.2	6
23	CRISPR-mediated deletion of the PECAM-1 cytoplasmic domain increases receptor lateral mobility and strengthens endothelial cell junctional integrity. Life Sciences, 2018, 193, 186-193.	4.3	5
24	Prevention of Fetal/Neonatal Alloimmune Thrombocytopenia in Mice: Biochemical and Cell Biological Characterization of Isoforms of a Human Monoclonal Antibody. ImmunoHorizons, 2022, 6, 90-103.	1.8	2
25	PECAM-1 Is a Negative Regulator of Platelet Activation by Laminin.. Blood, 2007, 110, 3655-3655.	1.4	0
26	Integrin $\alpha$ IIb $\beta$ 3-Mediated Outside-in Signaling: Brake or Amplifier of Platelet Activation?. Blood, 2014, 124, 4161-4161.	1.4	0
27	Conditional CRISPR-Mediated Deletion of Lyn Kinase Promotes Megakaryocyte Differentiation, Platelet Production and Function. Blood, 2020, 136, 30-30.	1.4	0